Abstract
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia, is a skin toxicity that could be observed during target therapies such as with tyrosine-kinase inhibitors (TKI). It usually develops within the first 2 - 4 weeks of drug administration. We present a case of HFS induced by Pazopanib after 2 months of treatment, in patients previously treated with Sunitinib, suggesting a possible cumulative toxicity of two drugs. The clinical and therapeutic management of skin adverse reactions during TKI therapy usually requires 25% dose reduction and adequate local treatment. It is important for the clinicians to recognize clinical signs and symptoms of such skin toxicities. Attention should be paid especially when two or more drugs from the same class are used in combined treatment.
Highlights
Sunitinib and Pazopanib are the most prescribed targeted therapies for the systemic management of advanced renal cell carcinoma (RCC)
Similar activity has been demonstrated against platelet-derived growth factor receptor (PDGFR)-α, PDGFR-β, fibroblast growth factor receptor (FGFR)-1, FGFR-3, and c-Kit [5]
Hand-foot syndrome (HFS), known as palmar-plantar erythrodysesthesia, is a frequently seen skin toxicity associated with chemotherapeutic agents like 5-fluorouracil, capecitabine and tyrosine-kinase inhibitors (TKI) like Sunitinib; less commonly with Pazopanib
Summary
Sunitinib and Pazopanib are the most prescribed targeted therapies for the systemic management of advanced renal cell carcinoma (RCC). Pazopanib is second-generation potent inhibitor of multiple protein targets involved in tumor cell proliferation and angiogenesis. In this process, several proangiogenic factors are involved, with a central role for the vascular endothelial growth factor (VEGF) family. Several proangiogenic factors are involved, with a central role for the vascular endothelial growth factor (VEGF) family Inhibition of this pathway has demonstrated antitumor activity in several tumor types, including renal cell carcinoma [4]. Hand-foot syndrome (HFS), known as palmar-plantar erythrodysesthesia, is a frequently seen skin toxicity associated with chemotherapeutic agents like 5-fluorouracil, capecitabine and tyrosine-kinase inhibitors (TKI) like Sunitinib; less commonly with Pazopanib. We present a case of HFS induced by Pazopanib after 2 months treatment, in a patient previously treated with Sunitinib
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
